We live in a golden age of biology. So why are people still dying from disease? Because discovery and development move slower than they should. Today, we’re partnering with Incyte to change that. Kosmos is now the first agent that can compress months of drug development into weeks, from the earliest stages of scientific discovery through to FDA approval. Incyte will be the first company to deploy it across their pipeline. Work that used to take a team of scientists months now happens in weeks. Patients can't wait, and neither can we. | 491 comments on LinkedIn
The Story behind the Science: Preprints of pandemic potential—how bioRxiv and medRxiv brought preprints to the life sciences
ABSTRACT The bioRxiv and medRxiv preprint servers brought preprinting to the life sciences and played a critical role in disseminating COVID research during the pandemic. Here, I reflect on the birth of bioRxiv and medRxiv and the crucial role so many members of the community played, our experience during the pandemic, and the launch of the new non-profit organization set up to oversee the servers. The pandemic was a stress test for bioRxiv and medRxiv that demonstrated their value and robustness. Under the umbrella of openRxiv, they are now poised to become long-term infrastructure underpinning a new publishing ecosystem.
Launching openRxiv Labs - openRxiv
Over the last thirteen years, bioRxiv and medRxiv have grown into widely used infrastructure for rapid research sharing in biology and medicine. The reliability and researcher-first values that have defined these platforms since their founding remain central to how we operate, and building on the trust, partnerships, and community relationships researchers worldwide depend on is…
Introducing Hypothesis commenting on bioRxiv and medRxiv: an updated way to engage with preprints - openRxiv
An important part of our mission at openRxiv is to collaborate with other organizations to improve science communication and promote interoperability. Preprints are just one part of the research workflow, and we want to ensure they are effectively integrated with the tools and communities that drive scientific progress. Today, we’re excited to share about another…
Jason Crawford on Twitter / X
It's hard to find information that all the world's top scientists and doctors have missed.But it's not that hard, if you're intelligent, thoughtful, and diligent, to find information that the medical system has not yet caught up to—information that is not yet incorporated into… pic.twitter.com/HrgGzCUdX2— Jason Crawford (@jasoncrawford) September 22, 2024
Jason Shepherd on Twitter / X
I have quite a lot of thoughts on this..that won't fit in a tweet. Bottomline is that there are issues scientists in the US would love to improve - faster review, less grant writing, more stability and freedom to do risky science. The folks celebrating this doc are mostly../1 https://t.co/xlPAH9XYNC— Jason Shepherd (@JasonSynaptic) July 23, 2026
Director Michael Kratsios on Twitter / X
In response to @POTUS's call for a revival of America's scientific enterprise, today I’m releasing Science: A New Golden Age.This report is a blueprint for renewing American scientific leadership for the 21st century. pic.twitter.com/ikM6pX2ndP— Director Michael Kratsios (@mkratsios47) July 21, 2026
Chris Beiser on Twitter / X
it'd be interesting to quantify the rate at which unaffiliated reddit users have improved on the state of the art for treatment protocols for diseases. my guess is that for 75% of diseases, they're responsible for a greater QoL increase than pharmaceutical companies over 10 years— Chris Beiser (@ctbeiser) June 7, 2021
Maybe scientific progress isn’t slowing, after all
A new paper takes aim at the claim that science has become less disruptive
Prof. Lee Cronin on Twitter / X
It is easy to see that biology does things that cannot be computed in advanced because the future is not controlled by statistics, it is controlled by creative actions. This means today’s statistically-driven GenAI is fundamentally unintelligent.— Prof. Lee Cronin (@leecronin) March 28, 2026
Dispatch
An occasional update on the lab’s latest findings, appearances, and happenings.
Accelerating life sciences research
Discover how a specialized AI model, GPT-4b micro, helped OpenAI and Retro Bio engineer more effective proteins for stem cell therapy and longevity research.
Patrick Collison on Twitter / X
Observing some people close to me with chronic health conditions, it's striking how useful Reddit frequently ends up being. I think a core reason is because trials aren’t run for a lot of things, and Reddit provides a kind of emergent intelligence that sits between that which any… pic.twitter.com/Eto23uQMDb— Patrick Collison (@patrickc) September 14, 2025
Ramez Naam on Twitter / X
There was a site years ago called CureTogether where patients could share information in a structured way on their disease, regimen, and progress, working towards a sort of bottoms-up clinical trial. 23andMe acquired them and it seems to be mostly dead.— Ramez Naam (@ramez) September 14, 2025
The Unaimed Arrow Never Misses
In this assay, Raphael Kopan argues that focused emphasis on disease and translation stifles innovation, and outline the reasons why, in my opinion, d…
Introducing GPT-Rosalind for life sciences research
OpenAI introduces GPT-Rosalind, a frontier reasoning model built to accelerate drug discovery, genomics analysis, protein reasoning, and scientific research workflows.
For Small Businesses
The Advanced Research Projects Agency for Health (ARPA-H) supports transformative research ranging in scale from molecular to societal to deliver health breakthroughs in years, not decades.
